AUDREY BETTINA MIKLIUS
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism DALLAS, TX NPI 1689628257
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism TX SANOFI-AVENTIS U.S. LLC All categories
General Payments — all program years on this page
$59,430.68
- Category: General Payments
- Program years: PY2018–2024
- Record count: 1,105
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $3,257.52 across 160 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,257.52 | 160 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $385.90 | 12 |
| Novo Nordisk AS | $354.78 | 17 |
| DEXCOM, INC. | $209.68 | 8 |
| Abbott Laboratories | $198.28 | 13 |
| Amgen Inc. | $189.35 | 11 |
| Insulet Corporation | $180.62 | 9 |
| MannKind Corporation | $173.50 | 11 |
| Lilly USA, LLC | $158.44 | 12 |
| Kyowa Kirin, Inc. | $126.11 | 3 |
| Radius Health, Inc. | $114.18 | 7 |
| Corcept Therapeutics | $104.63 | 5 |
| Antares Pharma, Inc. | $93.38 | 4 |
| PFIZER INC. | $90.75 | 5 |
| ABBVIE INC. | $83.61 | 5 |
| SHIELD THERAPEUTICS INC | $73.38 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $72.78 | 3 |
| Neurocrine BioSciences, Inc. | $69.26 | 3 |
| Ascendis Pharma Inc | $65.07 | 4 |
| Avvisto Therapeutics, LLC | $63.43 | 4 |
| BETA BIONICS, INC. | $52.74 | 4 |
| IBSA Pharma Inc. | $52.44 | 3 |
| CHIESI USA, INC. | $47.64 | 2 |
| CeQur Corporation | $42.48 | 1 |
| Amneal Pharmaceuticals LLC | $40.84 | 2 |
| Alvogen Inc | $36.90 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $33.67 | 2 |
| Tandem Diabetes Care, Inc. | $33.67 | 1 |
| Medtronic, Inc. | $31.70 | 2 |
| Averitas Pharma Inc. | $30.21 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $17.75 | 1 |
| Currax Pharmaceuticals LLC | $16.52 | 1 |
| Embecta Corp. | $13.83 | 1 |
By program year
Records — PY2024 (160)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.